葛根芩连汤及其单味药抗动脉粥样硬化的研究进展
Research Progress on Anti-Atherosclerosis of Gegen Qinlian Decoction and Its Single Medicine
DOI: 10.12677/ACM.2023.13122890, PDF,    科研立项经费支持
作者: 朱 琳：黑龙江中医药大学第一临床医学院，黑龙江 哈尔滨；周亚滨*：黑龙江中医药大学附属第一医院心血管二科，黑龙江 哈尔滨
关键词: 葛根芩连汤；动脉粥样硬化；炎症因子；作用机制；临床研究；Gegen Qinlian Decoction； Atherosclerosis； Inflammatory Factors； Mechanism of Action； Clinical Study
摘要: 动脉粥样硬化(atherosclerosis, AS)是诱发心血管疾病的重要危险因素之一。目前西医治疗已取得很大成效，但在控制病情发展的同时易耗伤正气，所以中医药治疗AS逐渐成为研究热点。葛根芩连汤出自《伤寒论》，尤擅清阳明经热毒，本文通过对葛根芩连汤治疗AS的主要机制及临床疗效进行了归纳分析，发现在临床实验方面葛根芩连汤可明显降低血脂水平，改善中医证候表现，减少斑块面积。在药理实验方面，单味中药研究中葛根芩连汤的有效成分包括葛根素、黄芩苷、小劈碱等分别发挥了不同程度的抗炎、抗氧化等功能；整体方药研究中葛根芩连汤能够抑制NLRP3炎症小体活化、激活Sirt1信号通路等来减缓AS的发生发展。因此，葛根芩连汤对AS疾病起到了抑制作用，值得后续进一步探索。
Abstract: Atherosclerosis (AS) is one of the important risk factors for cardiovascular diseases. At present, western medicine treatment has achieved great results, but it is easy to consume healthy qi while controlling the development of the disease, so Chinese medicine treatment of AS has gradually be-come a research hotspot. Gegen Qinlian Decoction is from Treatise on Febrile Diseases, and it is es-pecially good at clearing away the heat toxin in Yangming Meridian. This paper summarizes and analyzes the main mechanism and clinical efficacy of Gegen Qinlian Decoction in treating AS, and finds that Gegen Qinlian Decoction can obviously reduce the blood lipid level, improve the perfor-mance of TCM syndromes and reduce the plaque area in clinical experiments. In pharmacological experiments, the effective components of Gegen Qinlian Decoction, including puerarin, baicalin and sodium bicarbonate, have played different anti-inflammatory and antioxidant functions. Gegen Qin-lian Decoction can inhibit the activation of NLRP3 inflammatory bodies and activate Sirt1 signaling pathway to slow down the occurrence and development of AS. Therefore, Gegen Qinlian Decoction has an inhibitory effect on AS disease, which is worthy of further exploration.
文章引用：朱琳, 周亚滨. 葛根芩连汤及其单味药抗动脉粥样硬化的研究进展[J]. 临床医学进展, 2023, 13(12): 20549-20557. https://doi.org/10.12677/ACM.2023.13122890

参考文献

[1] Tsao, C.W., Aday, A.W., Almarzooq, Z.I., et al. (2022) Heart Disease and Stroke Statistics—2022 Update: A Report from the American Heart Association. Circulation, 145, E153-E639.
[2] 王新, 李春阳, 苏立平, 等. 动脉粥样硬化发病机制及治疗的研究进展[J]. 实用心脑肺血管病杂志, 2017, 25(2): 1-4.
[3] Punthakee, Z., Scully, L.J., Guindi, M.M. and Ooi, T.C. (2001) Liver Fibrosis Attributed to Lipid Lowering Medications: Two Cases. Journal of Internal Medicine, 250, 249-254. [Google Scholar] [CrossRef] [PubMed]
[4] 张金秀, 徐晖, 姜洪满. 某院500例住院患者他汀类药物应用情况分析[J]. 临床合理用药杂志, 2022, 15(36): 168-171.
[5] 续畅, 钟萌, 马致洁, 等. 葛根芩连汤的现代研究进展[J]. 吉林中医药, 2015, 35(6): 629-632.
[6] 刘莲萱, 吴威, 庞琳琳, 等. 葛根芩连汤化学成分、药理作用及临床应用研究进展[J]. 中华中医药学刊, 2022, 40(3): 147-154.
[7] 李在邠, 田秋芳. 葛根芩连汤的药理作用研究[J]. 中药药理与临床, 1990(5): 14-15.
[8] 李兆钰, 丁书文, 马度芳, 等. 基于心系疾病热毒学说探讨中医药抗炎治疗动脉粥样硬化[J]. 中华中医药杂志, 2021, 36(7): 3916-3920.
[9] 郑一, 郭鹤, 罗曦, 等. 基于网络药理学联合分子对接探究葛根芩连汤干预动脉粥样硬化的潜在分子机制[J]. 中国实验方剂学杂志, 2022, 28(11): 51-59.
[10] 赵兵, 王丹, 魏润生, 等. 葛根芩连汤治疗慢性牙周炎合并动脉粥样硬化的疗效及机制分析[J]. 检验医学与临床, 2017, 14(19): 2845-2847.
[11] 王佩军, 艾悦海, 魏永传, 等. 葛根芩连汤加减对颈动脉粥样硬化斑块的临床研究[J]. 中国医学创新, 2014, 11(28): 19-21.
[12] 郝媌, 丁元庆, 路玉良. 葛根芩连汤治疗高血压颈动脉粥样硬化临床研究[J]. 光明中医, 2013, 28(2): 273-275.
[13] 耿昌, 吴宏生, 韩玉晶, 等. 葛根芩连汤加失笑散辅助治疗毒热瘀阻型颈动脉粥样硬化临床观察[J]. 山西中医, 2022, 38(2): 51-52.
[14] 尹爱兵, 郝媌, 李筱媛. 针药并举联合西药治疗高血压颈动脉粥样硬化80例临床观察[J]. 中医杂志, 2015, 56(7): 590-593.
[15] Qiao, X., Wang, Q., Song, W., et al. (2016) A Chemical Profiling Solution for Chinese Medicine Formulas Using Comprehensive and Loop-Based Multiple Heart-Cutting Two-Dimensional Liquid Chroma-tography Coupled with Quadrupole Time-of-Flight Mass Spectrometry. Journal of Chromatography A, 1438, 198-204. [Google Scholar] [CrossRef] [PubMed]
[16] Li, J., Li, Y., Yuan, X., et al. (2023) The Effective Constituent Puerarin, from Pueraria lobata, Inhibits the Proliferation and Inflammation of Vascular Smooth Muscle in Atherosclero-sis through the miR-29b-3p/IGF1 Pathway. Pharmaceutical Biology, 61, 1-11. [Google Scholar] [CrossRef] [PubMed]
[17] Bao, M.H., Zhang, Y.W., Lou, X.Y., et al. (2014) Puerarin Protects Endothelial Cells from Oxidized Low Density Lipoprotein Induced Injuries via the Suppression of LOX-1 and Induction of eNOS. Canadian Journal of Physiology and Pharmacology, 92, 299-306. [Google Scholar] [CrossRef] [PubMed]
[18] Deng, Y., Lei, T.W., et al. (2018) ERK5/KLF2 Activation Is Involved in the Reducing Effects of Puerarin on Monocyte Adhesion to Endothelial Cells and Atherosclerotic Lesion in Apolipo-protein E-Deficient Mice. Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, 1864, 2590-2599. [Google Scholar] [CrossRef] [PubMed]
[19] Li, C.H., Gong, D., Chen, L.Y., et al. (2017) Puerarin Promotes ABCA1-Mediated Cholesterol Efflux and Decreases Cellular Lipid Accumulation in THP-1 Macrophages. European Journal of Pharmacology, 811, 74-86. [Google Scholar] [CrossRef] [PubMed]
[20] Yi, L., Jin, X., Chen, C.Y., et al. (2011) Chemical Structures of 4-Oxo-Flavonoids in Relation to Inhibition of Oxidized Low-Density Lipoprotein (LDL)-Induced Vascular Endothelial Dysfunction. International Journal of Molecular Sciences, 12, 5471-5489. [Google Scholar] [CrossRef] [PubMed]
[21] Wu, Y., Wang, F., Fan, L., et al. (2018) Baicalin Alleviates Atheroscle-rosis by Relieving Oxidative Stress and Inflammatory Responses via Inactivating the NF-κB and p38 MAPK Signaling Pathways. Biomedicine & Pharmacotherapy, 97, 1673-1679. [Google Scholar] [CrossRef] [PubMed]
[22] Ihling, C., Menzel, G., Wellens, E., et al. (1997) Topographical Association between the Cyclin-Dependent Kinases Inhibitor P21, p53 Accumulation, and Cellular Proliferation in Hu-man Atherosclerotic Tissue. Arteriosclerosis, Thrombosis, and Vascular Biology, 17, 2218-2224. [Google Scholar] [CrossRef] 
[23] Liu, Y., Jia, L., Min, D., et al. (2019) Baicalin Inhibits Prolifera-tion and Promotes Apoptosis of Vascular Smooth Muscle Cells by Regulating the MEG3/p53 Pathway Following Treatment with ox-LDL. International Journal of Molecular Medicine, 43, 901-913. [Google Scholar] [CrossRef] [PubMed]
[24] Liao, P., Liu, L., Wang, B., et al. (2014) Baicalin and Geniposide At-tenuate Atherosclerosis Involving Lipids Regulation and Immunoregulation in ApoE-/-Mice. European Journal of Pharmacology, 740, 488-495. [Google Scholar] [CrossRef] [PubMed]
[25] Wang, B., Liao, P.P., Liu, L.H., et al. (2016) Baicalin and Gen-iposide Inhibit the Development of Atherosclerosis by Increasing Wnt1 and Inhibiting Dickkopf-Related Protein-1 Ex-pression. Journal of Geriatric Cardiology, 13, 846-854.
[26] Zheng, X., Wang, P., Jia, M., et al. (2022) Baicalin Alle-viates Thrombin-Induced Inflammation in Vascular Smooth Muscle Cells. BioMed Research Internationa, 2022, Article ID: 5799308. [Google Scholar] [CrossRef] [PubMed]
[27] Rudijanto, A. (2007) The Role of Vascular Smooth Mus-cle Cells on the Pathogenesis of Atherosclerosis. Acta Medica Indonesiana, 39, 86-93.
[28] Doran, A.C., Meller, N. and McNamara, C.A. (2008) Role of Smooth Muscle Cells in the Initiation and Early Progression of Atherosclerosis. Arteri-osclerosis, Thrombosis, and Vascular Biology, 28, 812-819. [Google Scholar] [CrossRef] 
[29] Liu, Y.M., Wang, X., Nawaz, A., et al. (2011) Wogonin Ameliorates Lipotoxicity-Induced Apoptosis of Cultured Vascular Smooth Muscle Cells via Interfering with DAG-PKC Pathway. Acta Pharmacologica Sinica, 32, 1475-1482. [Google Scholar] [CrossRef] [PubMed]
[30] Wu, Y.H., Chuang, L.P., Yu, C.L., et al. (2019) Anticoagulant Effect of Wogonin against Tissue Factor Expression. European Journal of Pharmacology, 859, Article ID: 172517. [Google Scholar] [CrossRef] [PubMed]
[31] Tsai, K.L., Hung, C.H., Chan, S.H., et al. (2016) Baicalein Pro-tects against oxLDL-Caused Oxidative Stress and Inflammation by Modulation of AMPK-α. Oncotarget, 7, 72458-72468. [Google Scholar] [CrossRef] [PubMed]
[32] Zhang, Y., Ma, G., Li, C., et al. (2015) Bai-caleininhibits VSMCs Proliferation via Regulating LncRNAAK021954 Gene Expression. International Journal of Clin-ical and Experimental Medicine, 8, 22129-22138.
[33] Zhang, X., Qin, Y., Ruan, W., et al. (2021) Targeting Inflamma-tion-Associated AMPK//Mfn-2/MAPKs Signaling Pathways by Baicalein Exerts Anti-Atherosclerotic Action. Phyto-therapy Research, 35, 4442-4455. [Google Scholar] [CrossRef] [PubMed]
[34] Liang, K.W., Ting, C.T., Yin, S.C., et al. (2006) Berberine Suppresses MEK/ERK-Dependent Egr-1 Signaling Pathway and Inhibits Vascular Smooth Muscle Cell Regrowth after in Vitro Me-chanical Injury. Biochemical Pharmacology, 71, 806-817. [Google Scholar] [CrossRef] [PubMed]
[35] Lv, Y., Yang, H., Ye, P., et al. (2022) Berberine Inhibits Low Shear Stress-Induced Vascular Endothelial Inflammation via De-creasing Phosphorylation Of Akt and IRF3. Tissue Cell, 79, Article ID: 101946. [Google Scholar] [CrossRef] [PubMed]
[36] 罗纲, 向露, 姚平, 等. 槲皮素调控巨噬细胞胆固醇稳态改善载脂蛋白E敲除小鼠动脉粥样硬化[J]. 中国药理学通报, 2022, 38(9): 1395-1400.
[37] Du, F., Gesang, Q., Cao, J., et al. (2016) Isoliquiritigenin Attenuates Atherogenesis in Apolipoprotein E-Deficient Mice. International Journal of Molecular Sciences, 17, Article 1932. [Google Scholar] [CrossRef] [PubMed]
[38] Qi, J., Cui, J., Mi, B., et al. (2020) Isoliquiritigenin Inhibits Atherosclerosis by Blocking TRPC5 Channel Expression. Cardiovascular Therapeutics, 2020, Article ID: 1926249. [Google Scholar] [CrossRef] [PubMed]
[39] Yuan, L., Wang, D. and Wu, C. (2022) Protective Effect of Liquiritin on Coronary Heart Disease through Regulating the Proliferation of Human Vascular Smooth Muscle Cells via Upregulation of Sirtuin1. Bioengineered, 13, 2840-2850. [Google Scholar] [CrossRef] [PubMed]
[40] 郑一, 郭鹤, 包永睿, 等. 基于NF-κB/NLRP3/Caspase-1通路介导的巨噬细胞焦亡探究葛根芩连汤对动脉粥样硬化易损斑块的干预机制[J]. 中国实验方剂学杂志, 2022(11): 70-78.
[41] Kelley, N., Jeltema, D., Duan, Y. and He, Y. (2019) The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. International Journal of Molecular Sciences, 20, Article 3328. [Google Scholar] [CrossRef] [PubMed]
[42] 高宁, 任朋英, 姜丽丽, 等. 生物信息学法分析葛根芩连汤治疗心血管系统疾病的分子机理[J]. 华西药学杂志, 2019, 34(2): 187-191.
[43] Xia, Y. and Zweier, J.L. (1997) Superoxide and Peroxynitrite Generation from Inducible Nitric Oxide Synthase in Macrophages. Proceedings of the National Acad-emy of Sciences of the United States of America, 94, 6954-6958. [Google Scholar] [CrossRef] [PubMed]
[44] Ponnuswamy, P., Ostermeier, E., Schröttle, A., Nieswandt, B., Kuh-lencordt, P.J., et al. (2009) Oxidative Stress and Compartment of Gene Expression Determine Proatherosclerotic Effects of Inducible Nitric Oxide Synthase. The American Journal of Pathology, 174, 2400-2410. [Google Scholar] [CrossRef] [PubMed]
[45] 万函, 王秀芬, 杨美雯, 杨蓓, 吴磊, 洪芬芳, 杨树龙. 一氧化氮信号通路与动脉粥样硬化[J]. 南昌大学学报(医学版), 2021, 61(5): 72-78.
[46] 郑一, 郭鹤, 罗曦, 等. 葛根芩连汤调控巨噬细胞极化趋势干预ApoE-/-小鼠AS易损斑块机制[J]. 中国实验方剂学杂志, 2022, 28(11): 60-69.
[47] 郑国斌, 马传瑞, 樊官伟. 葛根芩连汤治疗动脉粥样硬化的药理学基础研究进展[J]. 天津中医药大学学报, 2022, 41(5): 668-674.

为你推荐